Combining oncology drug development and biomarker technology experience to improve cancer care
Thomas H. Adams, Ph.D.
Dr. Adams has served as Executive Chairman since May 2020 and formerly as Chairman of the Board since April 2009 and as Chief Executive Officer from June 2018 to May 2020. He is currently a Director at Hepion Pharmaceuticals, Inc. where he has served since 2014. Previously, Dr. Adams served as Chairman of Clearbridge BioPhotonics, Inc., an imaging solutions company, from 2013 to 2019, and as Director of Synergy Pharmaceuticals, Inc. from 2009 to 2019. He served in several leadership roles at IRIS International, including Director, Head of Personalized Medicine and Chief Technology Officer, from 2005 until the company’s acquisition by Danaher Corporation in 2012. From 1998 to 2006, Dr. Adams was Chairman and Chief Executive Officer of Leucadia Technologies, a privately held biotechnology company which was acquired by IRIS International, Inc. in 2006. Dr. Adams founded Genta, Inc. in 1989 and served as its Chief Executive Officer until 1997. He also founded Gen-Probe, Inc. in 1984 and served as Chairman and Chief Executive Officer until its acquisition by Chugai Biopharmaceuticals, Inc. in 1989. Dr. Adams holds a Ph.D. in Biochemistry from the University of California, Riverside. The Board believes that Dr. Adams’ executive leadership and the extensive healthcare expertise he has developed qualifies Dr. Adams to serve as a director of our company.